|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:approves
|
gptkb:2005
|
|
gptkbp:atccode
|
N06 BA12
|
|
gptkbp:available_on
|
generic version
|
|
gptkbp:brand
|
gptkb:Focalin
|
|
gptkbp:casnumber
|
2200-59-3
|
|
gptkbp:chemical_formula
|
C14 H19 NO2
|
|
gptkbp:class
|
gptkb:pharmaceuticals
|
|
gptkbp:clinical_trial
|
Phase IV
|
|
gptkbp:condition
|
gptkb:Attention_Deficit_Hyperactivity_Disorder
|
|
gptkbp:contraindication
|
gptkb:Ophthalmology
heart problems
hyperthyroidism
history of drug abuse
|
|
gptkbp:controlled_substance_schedule
|
Schedule II
|
|
gptkbp:dosage_form
|
gptkb:capsule
|
|
gptkbp:duration
|
up to 12 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:formulation
|
extended-release capsule
|
|
gptkbp:healthcare
|
gptkb:true
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Focalin XR
|
|
gptkbp:ingredients
|
gptkb:dexmethylphenidate
|
|
gptkbp:interacts_with
|
antidepressants
MAO inhibitors
antihypertensives
other stimulants
|
|
gptkbp:is_monitored_by
|
blood pressure
heart rate
growth in children
|
|
gptkbp:legal_status
|
Prescription only
|
|
gptkbp:lifespan
|
12 hours
|
|
gptkbp:manufacturer
|
gptkb:Novartis
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:packaging
|
gptkb:bottle
|
|
gptkbp:patient_education
|
avoid alcohol
store at room temperature
do not crush or chew
take as prescribed
report any mood changes
|
|
gptkbp:premiered_on
|
1 to 2 hours
|
|
gptkbp:requires
|
gptkb:true
|
|
gptkbp:route_of_administration
|
oral
|
|
gptkbp:side_effect
|
anxiety
nausea
decreased appetite
insomnia
dry mouth
|
|
gptkbp:strength
|
10 mg
5 mg
15 mg
20 mg
30 mg
|
|
gptkbp:used_for
|
ADHD
|
|
gptkbp:bfsParent
|
gptkb:Sannin
|
|
gptkbp:bfsLayer
|
5
|